Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Venture
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

MPH:CN

1.9100 CAD 0.0100 0.53%

As of 15:58:02 ET on 03/27/2015.

Snapshot for Medicure Inc (MPH)

Open: 1.9900 Day's Range: 1.9100 - 2.0000 Volume: 7,433
Previous Close: 1.9000 52wk Range: 0.7500 - 3.1500 1-Yr Rtn: +101.05%

Stock Chart for MPH

No chart data available.
  • MPH:CN 1.9100
  • 1D
  • 1M
  • 1Y
1.9000
Interactive MPH Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for MPH

Current P/E Ratio (ttm) 191.0000
Estimated P/E(05/2015) 15.9167
Relative P/E vs. SPTSX 9.8474
Earnings Per Share (CAD) (ttm) 0.0100
Est. EPS (CAD) (05/2015) 0.1200
Est. PEG Ratio -
Market Cap (M CAD) 23.71
Shares Outstanding (M) 12.42
30 Day Average Volume 14,795
Price/Book (mrq) -
Price/Sale (ttm) 3.6238
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement -
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for MPH

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for MPH

Medicure Inc. is a cardiovascular drug discovery and development company focused on developing therapeutics for unmet needs in the field of cardiovascular medicine. The Company's current focus is on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke.

Albert D FriesenChairman/CEO/FounderDawson J ReimerPresident/COO
James F KinleyCFO/Secretary
More Company Profile & Key Executives for MPH

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil